Talimogene laherparepvec + nivolumab + trabectedin for sarcoma

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 22 Mar 2019: Trial registered, NCT03886311
  2. 15 May 2019: Trial started, NCT03886311

The trials

NCT03886311: Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma

State
Under way
Phase
Phase 2
People
200 planned
Started
15 May 2019
Primary completion
31 Dec 2030
Arms
Talimogene laherparepvec, Nivolumab and Trabectedin
Results
None posted
  1. 22 Mar 2019: Trial registered
  2. 15 May 2019: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.